Last reviewed · How we verify

NCT05993494

Pain, Central Sensitization, Kinesiophobia and Stress Level in Individuals With Temporomandibular Dysfunction

Completed Last updated 17 July 2025
What this trial tests

trial in Temporomandibular Joint Disorders in 90 participants. Completed in 30 May 2025.

Timeline
15 May 2023
Primary endpoint
20 February 2025
30 May 2025

Quick facts

Lead sponsorKaradeniz Technical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date15 May 2023
Primary completion20 February 2025
Estimated completion30 May 2025
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Karadeniz Technical University

Who can join

Adults 18 to 65, any sex, with Temporomandibular Joint Disorders or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Temporomandibular dysfunction (TMD) is a musculoskeletal and neuromuscular system-related condition that affects the masticatory muscles, temporomandibular joint, and other related structures. Recent research has focused specifically on pain catastrophe, kinesiophobia, and central sensitization in individuals with TMD. Therefore, the aim of this study is to examine the relationship between pain, central sensitization, kinesiophobia and stress level in individuals with temporomandibular dysfunction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Temporomandibular Joint Disorders

Currently open trials in the same condition.

Other Karadeniz Technical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05993494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing